Your search did not match any results.
We suggest you try the following to help find what you’re looking for:
For sponsors, improving oversight of study startup means real-time visibility into the progress of studies outsourced to their CRO partners, and transitioning away from tactical projects toward strategic partnerships, with both stakeholders having a vested interest.
Oracle Analyze Insight for Activate Cloud Service intelligence improves transparency, communication, and collaboration with CROs by providing sponsors with timely status updates and operational insights into outsourced studies with their CRO partners, leading to enhanced performance and governance. Through visually rich analytics and dashboards, we help transition your team from a process that is reactive to one that is more proactive.
Learn how fundamental to new ICH guidelines is the modernization of processes and technology with a focus on QbD and risk-based management approaches.
Learn how machine learning technologies can help predict outcomes in clinical trials, leading to faster drug approval times and lower costs.
Learn how to overcome the complexities introduced in outsourced studies (e.g., quality, oversight, collaboration, and governance).
Learn how entrenched silos have stymied data flow efforts due to minimal understanding of what is needed downstream.
Drive competitive performance and operational excellence by focusing on bottlenecks and processes ripe for optimization.
Learn how good clinical practice (GCP) guidelines and systems help improve overall study quality.
Learn how contemporariness can be defined in operational SOPs and implemented in daily operations to ensure audit readiness.
Learn how to tackle the challenge of improving budget and contract cycle times in starting clinical trials.
Discover how to combat poor risk management practices that have fueled the rescue study industry.
Hear how eClinical technologies and industry initiatives are impacting the ability of investigative sites to conduct clinical trials.
Learn how to mitigate the patient and data quality risks associated with decentralized clinical trials.